AnaptysBio (NASDAQ:ANAB – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses ...

AnaptysBio has cautioned that these forward-looking statements are subject to risks and uncertainties, including the company's ability to execute its product development and commercialization plans.

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its ...

AnaptysBio, Inc. has announced a Stock Repurchase ... including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ...

Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticipates receipt of a $75 million commercial sales milestone payment from GSK in 2025 or ...

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company ...

Discovering AnaptysBio: A Closer Look AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in ...

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq ... related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately ...

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq ... including risks and uncertainties related to the company's ability to advance its product candidates, obtain regulatory ...